Table 1. Patient baseline characteristics.
| Characteristic | Outcome (total=107) |
|---|---|
| Median age [range] (years) | 69 [34–84] |
| Gender, male, n [%] | 95 [87] |
| ECOG PS at start of nivolumab, n [%] | |
| 0 | 20 [19] |
| 1 | 68 [64] |
| 2 | 6 [5] |
| Unknown | 13 [12] |
| Histological subtype, n [%] | |
| Epithelioid | 78 [73] |
| Mixed/sarcomatoid | 22 [20] |
| Unknown | 7 [7] |
| Best response to previous platinum-based chemotherapy, n [%] | |
| PD | 28 [26] |
| SD | 46 [43] |
| PR | 28 [26] |
| CR | 1 [1] |
| Unknown (not reported) | 4 [4] |
| Line of treatment, n [%] | |
| 2 | 97 [91] |
| ≥3 | 10 [9] |
| Stage at start of nivolumab, n [%] | |
| I/II | 32 [30] |
| III/IV | 70 [65] |
| Unknown | 5 [5] |
| PD-L1 status, n [%] | |
| Negative | 22 [20] |
| Positive | 11 [10] |
| Unknown | 74 [70] |
Data are presented as absolute number with according percentages, unless stated otherwise. ECOG PS, Eastern Cooperative Oncology Group Performance Status; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; PD-L1, programmed death ligand 1.